Sloan Sheldon bought SYRE
May 1, 2026 · Form 4 insider transaction
Sloan Sheldon bought 78,333 shares of Spyre Therapeutics, Inc. at $27.46 per share, a transaction worth $2.15M. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
78,333
Price
$27.46
Total value
$2.15M
InsiderSloan Sheldon
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMay 1, 2026
Filing dateMay 1, 2026
Shares owned after78,333
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.